O'Reilly Michael S
Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, 77030, USA.
Semin Radiat Oncol. 2006 Jan;16(1):45-50. doi: 10.1016/j.semradonc.2005.08.006.
Angiogenesis is critical for a number of physiologic and pathophysiologic processes, and angiogenesis inhibitors are now being used in the treatment of cancer. Although antiangiogenic agents offer great therapeutic potential, preclinical and clinical trial results suggest that these agents will have a delayed onset of activity and may only induce disease stabilization for patients with advanced malignancy. The use of radiation therapy for cancer is also associated with therapeutic challenges that are distinct from those that might be expected with antiangiogenic agents. Thus, the use of angiogenesis inhibitors in combination with radiation therapy should help to overcome the limitations of each leading to enhanced efficacy and diminished toxicity. The goal of this review is to provide an overview and discussion of the combination of angiogenesis inhibitors with radiation therapy.
血管生成对许多生理和病理生理过程至关重要,血管生成抑制剂目前正用于癌症治疗。尽管抗血管生成药物具有巨大的治疗潜力,但临床前和临床试验结果表明,这些药物的活性起效会延迟,对于晚期恶性肿瘤患者可能仅能诱导疾病稳定。癌症放射治疗的应用也面临着与抗血管生成药物不同的治疗挑战。因此,联合使用血管生成抑制剂与放射治疗应有助于克服各自的局限性,从而提高疗效并降低毒性。本综述的目的是对血管生成抑制剂与放射治疗的联合应用进行概述和讨论。